ORADUR® Abuse-deterrent Technology

ORADUR technology is focused on two interrelated problems: extending the therapeutic duration of conventional short-acting drugs and protecting the resulting high drug loads against tampering and improper extraction.

Proprietary ORADUR gel matrices accommodate high concentrations of active compound, allowing for once- and twice-daily dosing while providing formidable built-in resistance to improper release or extraction. ORADUR-based oxycodone capsules, in development for the management of chronic pain, resist the most common forms of tampering, such as crushing and dissolving in liquids. As a result, they serve as excellent deterrents to abuse by snorting, smoking, injecting, chewing, and drinking. ORADUR-based methylphenidate capsules, in development for the treatment of attention-deficit hyperactivity disorder (ADHD), exhibit similar preventative properties with regard to stimulant abuse

ORADUR advantages:

  • Class-leading tamper resistance
  • High drug loads, compatible with infrequent dosing
  • Near-zero-order release kinetics
  • Standard manufacturing and encapsulation process, for low-cost scalability
  • Pre-cleared inactive pharmaceutical ingredients

Learn more about ORADUR-based pipeline products:

REMOXY® ER (ORADUR®-Oxycodone)